RT Journal Article
SR Electronic
T1 Efficient and accurate simulation of infectious diseases on adaptive networks
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.02.24318307
DO 10.1101/2024.12.02.24318307
A1 Gubela, Nils
A1 von Kleist, Max
YR 2024
UL http://medrxiv.org/content/early/2024/12/03/2024.12.02.24318307.abstract
AB Mathematical modelling of infectious disease spreading on temporal networks has recently gained popularity in complex systems science to understand the intricate interplay between social dynamics and epidemic processes. While analytic solutions for these systems can usually not be obtained, numerical studies through exact stochastic simulation has remained infeasible for large, realistic systems.Here, we introduce a rejection-based stochastic sampling algorithm with high acceptance probability (‘high-acceptance sampling’; HAS), tailored to simulate disease spreading on adaptive networks. We proof that HAS is exact and can be multiple orders faster than Gillespie’s algorithm. While its computational efficacy is dependent on model parameterization, we show that HAS is applicable regardless on whether contact dynamics are faster, on the same time-scale, or slower than the concurrent disease spreading dynamics. The algorithm is particularly suitable for processes where the spreading- and contact processes are co-dependent (adaptive networks), or when assumptions regarding time-scale separation become violated as the process unfolds. To highlight potential applications, we study the impact of diagnosis- and incidence-driven behavioural changes on virtual Mpox- and COVID-like epidemic and examine the impact of adaptive behaviour on the spreading processes.Author Summary Infectious disease spreading is often affected by the dynamics of human-human contacts. These contact dynamics may change over time, and in direct response to infection kinetics, through e.g. self-isolation, risk-aversion, or any adaptive behaviour, which can generate complex dynamics as seen in recent outbreaks with e.g. COVID-19, as well as Mpox clade IIb (2022). Agent-based models (ABMs) are often derived and numerically simulated to study the complex interplay between epidemic- and contact dynamics and to derive insights for disease control. However, numerical simulation of these models denotes a computational bottleneck and limits the applicability of large ABMs. We introduce a novel numerical method called ‘high-acceptance sampling’ (HAS), which allows for the exact simulation of outbreaks with adaptive contact behaviour. We proof that HAS is exact, show that it is faster, and that runtime grows with at least an order of magnitude less than state-of-the art exact simulation methods. This enables simulation of outbreaks on large populations, as well as parameter estimation for large systems. We apply HAS to study an Mpox- and COVID-like pandemic and the impact of adaptive behaviour on different time-evolving contact networks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy - The Berlin Mathematics Research Center MATH+ (EXC-2046/1, project ID: 390685689).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study only used simulated data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors